irinotecan has been researched along with Bilateral Wilms Tumor in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Erickson, SW; Gorlick, R; Guo, Y; Houghton, PJ; Kolb, EA; Kurmasheva, RT; Maris, JM; Mosse, YP; Smith, MA; Teicher, BA | 1 |
| Bandyopadhyay, A; Chen, Y; Erickson, SW; Houghton, PJ; Kurmashev, D; Kurmasheva, RT; Lai, Z; Phelps, DA; Robles, AJ; Smith, MA | 1 |
| Clerico, A; Collini, P; Schiavetti, A; Varrasso, G | 1 |
| Bergeron, C; Brok, J; Catania, S; Graf, N; Hol, JA; Howell, L; Kager, L; Mavinkurve-Groothuis, AMC; Pritchard-Jones, K; Spreafico, F; van den Heuvel-Eibrink, MM; van Tinteren, H; Verschuur, A | 1 |
| Büyükkapu Bay, S; Çakır, FB; Darendeliler, E; Görgün, O; Kebudi, R; Zülfikar, B | 1 |
| Malogolowkin, MH; Mascarenhas, L; Venkatramani, R | 1 |
| Hanada, R; Kawa, K; Manabe, A; Matsunaga, T; Mimaya, J; Mugishima, H; Shimada, A; Shitara, T; Sugimoto, T; Tsuchida, Y; Tsurusawa, M | 1 |
2 trial(s) available for irinotecan and Bilateral Wilms Tumor
| Article | Year |
|---|---|
Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group.
Topics: Adolescent; Camptothecin; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Irinotecan; Kidney Neoplasms; Male; Risk Factors; Wilms Tumor | 2018 |
Irinotecan for children with relapsed solid tumors.
Topics: Camptothecin; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Male; Neoplasms; Neuroblastoma; Recurrence; Remission Induction; Rhabdomyosarcoma; Tumor Burden; Wilms Tumor | 2006 |
5 other study(ies) available for irinotecan and Bilateral Wilms Tumor
| Article | Year |
|---|---|
Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Child; Female; Humans; Irinotecan; Kidney Neoplasms; Mice; Mice, SCID; Neoplasms, Experimental; Neuroblastoma; Pyrazoles; Pyrimidinones; Wilms Tumor; Xenograft Model Antitumor Assays | 2020 |
Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Female; Furans; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Ketones; Kidney Neoplasms; Mice; Mice, SCID; Prognosis; Rhabdomyosarcoma; Tumor Cells, Cultured; Vincristine; Wilms Tumor; Xenograft Model Antitumor Assays | 2020 |
Vincristine, Irinotecan, and Bevacizumab in Relapsed Wilms Tumor With Diffuse Anaplasia.
Topics: Anaplasia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Child; Child, Preschool; Female; Humans; Irinotecan; Kidney Neoplasms; Male; Vincristine; Wilms Tumor | 2018 |
Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Neuroblastoma; Osteosarcoma; Remission Induction; Retreatment; Rhabdomyosarcoma; Sarcoma, Ewing; Survival Rate; Temozolomide; Vincristine; Wilms Tumor | 2019 |
Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Child; Dacarbazine; Female; Humans; Irinotecan; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Temozolomide; Vincristine; Wilms Tumor | 2014 |